Faron Pharmaceuticals

Faron Pharmaceuticals

Company type	Public
Traded as	AIM: FARN
Industrie	Biopharmaceutical, Healthcare
Gegründet	2003
Gründer	Markku Jalkanen and others
Hauptsitz	Turku, Finland
Key people	Markku Jalkanen CEO
Produkte	Traumakine, Clevegen
Website	http://www.faron.com/

Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.

The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.

Its lead product Traumakine has been developed to treat Acute Respiratory Distress Syndrome (ARDS). It is currently (2019) undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatmant patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced.

In 2020 Traumakine was selected to take part in the WHO Solidarity trial and Remap-Cap trials to find drugs for the symptoms of Covid_19

Faron’s other products include the anti-Clever-1 antibody Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach. Current encouraging phase I/II clinical trials in Europe are soon to be extended to America.

Faron Pharmaceuticals is listed in London on the London Stock Exchange's Alternative Investment Market (AIM).